Introduction
• Although short-and long-term graft survival after renal transplantation improved substantially during the 1980s and 1990s, 1 more recent data suggest that long-term graft survival has not improved to the same extent as short-term rates, and that improvements in acute rejection rates do not necessarily predict better graft survival.
2
• Antibody-mediated rejection (AbMR) has been highlighted as a key clinical factor limiting improvements in long-term renal transplantation outcomes.
3
• Patients who are non-adherent to post-transplant immunotherapy show markedly higher rates of AbMR than adherent patents. 4 • Poor adherence to immunosuppressive regimens, which is reportedly more prevalent in renal transplantation than in other solid organ transplant types, 5 is associated with increased treatment regimen complexity and dosing frequency ('pill burden'). 6, 7 • As most UK renal transplant patients are treated with tacrolimus twice daily in an immediate-release (IR) formulation (Prograf ® ) as part of a multidrug regimen, there is an unmet need for reduced pill burden in these allograft recipients.
Objectives
• To investigate the cost implications of using once-daily prolonged-release (PR) formulation of tacrolimus (Advagraf ® ) in place of twice-daily IR tacrolimus as the primary immunosuppression in patients undergoing renal transplantation in the UK National Health Service (NHS).
• To identify the key drivers associated with cost outcomes.
Methods

Model description
• A budget impact model was developed in Microsoft ® Excel and applied to renal transplant patients using IR tacrolimus or PR tacrolimus as primary immunosuppressive medication.
• The model consisted of a decision tree followed by a four-state Markov process ( Figure 1 ). ➢ The decision tree divided IR and PR tacrolimus patients into adherent (78.8% and 88.2%, respectively) and non-adherent (21.2% and 11.8%, respectively) categories on the basis of randomised clinical trial data. • Transition probabilities for graft failure and patient mortality in adherent and non-adherent patients were derived as follows: ➢ 2012-2013 NHS organ transplantation data 9 were used to establish baseline proportions of grafts and patients surviving at 1, 2 and 5 years after transplantation ➢ the relative risk of graft failure (5.15) in non-adherent versus adherent patients was derived from a study of 315 kidney transplant recipients followed for ≤32 years (median 31.4 months) after transplantation 4 ➢ AbMR rates were based on donor-specific antibody (DSA) formation in 20 of 26 non-adherent patients and 84 of 289 adherent patients.
4
• The base-case analysis (based on the Edinburgh Renal Unit protocol 10 ) assumed management of AbMR with: ➢ 500 mg intravenous methylprednisolone daily for 3 days ➢ five plasma exchanges and five intravenous immunoglobulin infusions per plasma exchange (total of 25 x 100 mg/kg infusions) ( Table 1 ).
• Additional DSA monitoring and renal biopsy costs associated with diagnosis were conservatively excluded from the analysis.
• The time horizon was 5 years.
• All costs were reported in 2014 pounds sterling (GBP).
• No discounting or retransplantation costs were applied.
Study cohort
• The study cohort was based on a multicentre, randomised trial of PR and IR tacrolimus in 667 de novo transplant recipients. 16 Assumptions were: 
Sensitivity analyses
• To identify cost and outcome drivers, a series of sensitivity analyses were performed based on alternative time horizons; 3.5% discount rate; alternative relative risks for graft failure; and different AbMR treatment regimens.
Results
Base case
• Switching patients from IR tacrolimus to the PR formulation resulted in a projected cost saving over 5 years ( Figure 2 ).
➢ Mean projected total costs with PR tacrolimus were £40,974 versus £45,836 with IR tacrolimus, translating to cost savings of £4,862 per patient and £486,200 in a hypothetical 100-patient cohort.
➢ The cost savings with PR tacrolimus were largely derived from reduced costs associated with dialysis costs (-£3,916.15) , and, to a lesser extent, reduced costs associated with AbMR (-£424.24). • Increased dialysis and AbMR costs with IR tacrolimus were driven by:
➢ higher rates of non-adherence to primary immunosuppression ( Figure 1) ➢ consequently increased incidence of graft failure ( Figure  3 ). One-way sensitivity analysis
• Removal of AbMR costs from the analysis reduced PR tacrolimus and IR tacrolimus costs by £6,818 and £7,014, respectively, compared with the base-case results (Table 2 ).
• The sensitivity analysis showed the base-case findings to be robust (Table 2) .
➢ Cost savings increased as the time horizon was widened.
➢ The application of discounting had a negligible effect.
➢ PR tacrolimus remained cost-saving relative to IR tacrolimus, when graft failure risk was assumed to be the same in adherent and non-adherent patients; when alternative (lower) graft failure relative risks were applied; when the costs of both formulations were assumed to be same; and irrespective of the AbMR regimen chosen.
Strengths
• The modelling approach was transparent and robust.
• Up-to-date, UK-specific data for underlying graft rejection and mortality rates, treatment-related costs and resource-use assumptions were used.
Limitations
• Data were derived from heterogeneous populations.
• Only a limited cross-section of possible treatment modalities proposed for AbMR management was modelled.
• No difference in mortality was assumed between PR or IR tacrolimus and between adherent and non-adherent patients.
• AbMR diagnostic costs were not captured by the model; the absolute cost projections presented here may therefore be underestimated.
Conclusions
• This modelled analysis showed that PR tacrolimus used in place of IR tacrolimus in renal transplant recipients in a UK healthcare system setting was associated with lower dialysis and AbMR treatment-related costs.
• Improved adherence to PR tacrolimus relative to IR tacrolimus appears to drive reductions in AbMR and dialysis costs, with consequent reductions in rates of graft loss and onset of AbMR. 
